News

The OcuMet Beacon is a proprietary, noninvasive tool for assessing retinal health. The company said it will be available on the US market for use in clinics and health care institutions.

Explore the challenges and strategies of private practice management, focusing on financial sustainability and patient care in today's healthcare landscape.

The clearance expands its existing label from patients aged 4 to 7 years to patients aged 4 to under 13 years.

The OcuMet Beacon is a proprietary, noninvasive tool for assessing retinal health. The company said it will be available on the US market for use in clinics and healthcare institutions.

Retina World Congress 2025 unites global retina experts in Fort Lauderdale to explore cutting-edge research, surgical techniques, and patient care advancements.

4D-150 is a potential backbone therapy that is designed to provide multiyear sustained delivery of anti-VEGF (aflibercept and anti–VEGF-C) to be targeted to the retina with a single, well-tolerated intravitreal injection.

Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor.

LuxIA is designed to screen adult diabetic patients for more-than-mild diabetic retinopathy.

In the weeks to come, the European Commission will issue a decision on the first severe thyroid eye disease treatment

A novel vitrectomy device shows promising safety and efficacy in the targeted removal of symptomatic vitreous opacities in pseudophakic eyes

Prevent Blindness has declared May the second annual inherited retinal disease and genetic testing month, offering free resources on education and other awareness efforts.

A large international study reported a genetic link between schizophrenia and retinal status.

Alex Hacopian, MD, highlights how a recent ambispective study demonstrated strong visual acuity outcomes and patient satisfaction following bilateral implantation of an advanced presbyopia-correcting intraocular lens.

Researchers evaluate key measures for tracking disease progression in Usher syndrome type 2–related retinal degeneration

STAR-GLOBAL is an extension trial of the initial EU clinical trials investigating the long term safety and efficacy of MINIject in patients with glaucoma with up to 5 years of follow up.

Topcon Healthcare appoints Daniela Ferrara, MD, PhD, as Chief Medical Officer to enhance AI-driven ocular imaging and advance digital healthcare solutions.

Lisa Nijm, MD, says preoperative osmolarity testing can help clinicians manage patient expectations and improve surgical results.

Ultraviolet light’s potential in ocular care extends beyond structural reinforcement to antimicrobial applications, especially for microbial keratitis

Responder analysis was conducted to evaluate the percentage of patients achieving complete symptom resolution across 13 prespecified symptom end points.

Brazilian researchers reveal how choroidal thickness influences treatment response in diabetic macular edema, enhancing personalized therapy strategies.

Endoscopic cyclophotocoagulation (ECP) has major potential for patients with glaucoma

The retrospective study assessed corneal cross-linking complications at Wills Eye Hospital from 2018 to 2023.

Topcon Healthcare has appointed Daniela Ferrara, MD, PhD, as chief medical officer to lead the company’s clinical and medical strategy.

A two-way foot bridge between eye care and mental health.